Differences Between Randomized Clinical Trial Patients and Real-World Initiators of the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide

Real World ◽

Receptor Agonist ◽

Glucagon Like Peptide ◽

A phase 3 randomized clinical trial using a o nce‐weekly glucagon‐like peptide‐1 receptor agonist in adolescents and young adults with hypothalamic obesity

Diabetes Obesity and Metabolism ◽

10.1111/dom.14224 ◽

2020 ◽

Author(s):

Christian L. Roth ◽

Francisco A. Perez ◽

Kathryn B. Whitlock ◽

Clinton Elfers ◽

Jack A. Yanovski ◽

...

Keyword(s):

Clinical Trial ◽

Young Adults ◽

Receptor Agonist ◽

Adolescents And Young Adults ◽

Hypothalamic Obesity ◽

Phase 3 ◽

Glucagon Like Peptide ◽

Glucagon-Like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors, and Risk of Acute Pancreatitis: A Meta-analysis of Randomized Clinical Trial and Review of Literature

The American Journal of Gastroenterology ◽

10.14309/00000434-201510001-00020 ◽

2015 ◽

Vol 110 ◽

pp. S10

Author(s):

Stanley Yakubov ◽

Kevin Tin ◽

EiEi P. Soe ◽

Dmitriy O. Khodorskiy ◽

Kambiz Kadkhodayan ◽

...

Keyword(s):

Clinical Trial ◽

Acute Pancreatitis ◽

Meta Analysis ◽

Dipeptidyl Peptidase ◽

Review Of Literature ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitors ◽

Glucagon Like Peptide ◽

PDB17 - REAL-WORLD DOSING BEHAVIOURS AND OUTCOMES WHEN SWITCHING TO IDEGLIRA FROM A FREE COMBINATION OF INSULIN AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST THERAPY

Value in Health ◽

10.1016/j.jval.2018.09.723 ◽

2018 ◽

Vol 21 ◽

pp. S121

Author(s):

H. Price ◽

B. Schultes ◽

R. Prager ◽

J. Fernandes ◽

J.B. Møller ◽

...

Keyword(s):

Real World ◽

Receptor Agonist ◽

Agonist Therapy ◽

Glucagon Like Peptide ◽

Abstract #290: Real-World Persistence and HBA1C Goal Attainment in Patients with Type Ii Diabetes Mellitus Initiated on Canagliflozin or a Glucagon-Like Peptide-1 Receptor Agonist

Endocrine Practice ◽

10.1016/s1530-891x(20)44410-6 ◽

2017 ◽

Vol 23 ◽

pp. 80

Author(s):

Patrick Lefebvre ◽

Dominic Pilon ◽

Mike Ingham ◽

Marie-Hélène Lafeuille ◽

Bruno Emond ◽

...

Keyword(s):

Diabetes Mellitus ◽

Real World ◽

Type Ii Diabetes ◽

Receptor Agonist ◽

Goal Attainment ◽

Type Ii Diabetes Mellitus ◽

Type Ii ◽

Glucagon Like Peptide ◽

Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence

Obesity Science & Practice ◽

10.1002/osp4.116 ◽

2017 ◽

Vol 3 (3) ◽

pp. 342-351 ◽

Cited By ~ 12

Author(s):

G. S. Carls ◽

R. Tan ◽

J. Y. Zhu ◽

E. Tuttle ◽

J. Yee ◽

...

Keyword(s):

Type 2 Diabetes ◽

Medication Adherence ◽

Real World ◽

Weight Change ◽

Receptor Agonist ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Glucagon Like Peptide ◽

Erratum to: Lower Ghrelin Levels and Exaggerated Postprandial Peptide-YY, Glucagon-Like Peptide-1, and Insulin Responses, After Gastric Fundus Resection, in Patients Undergoing Roux-en-Y Gastric Bypass: A Randomized Clinical Trial

Obesity Surgery ◽

10.1007/s11695-012-0843-5 ◽

2012 ◽

Vol 23 (3) ◽

pp. 425-425 ◽

Cited By ~ 1

Author(s):

Aikaterini Chronaiou ◽

Marina Tsoli ◽

Ioannis Kehagias ◽

Michalis Leotsinidis ◽

Fotis Kalfarentzos ◽

...

Keyword(s):

Clinical Trial ◽

Gastric Bypass ◽

Peptide Yy ◽

Gastric Fundus ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Insulin Responses

Real-World Comparative Effectiveness, Treatment Patterns, and Costs in Type 2 Diabetes Mellitus (T2DM) Patients Initiated on Canagliflozin 300 mg (CANA) or a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1)

Diabetes ◽

10.2337/db18-1287-p ◽

2018 ◽

Vol 67 (Supplement 1) ◽

pp. 1287-P

Author(s):

MUKUL SINGHAL ◽

HIANGKIAT (JASON) TAN ◽

CRAIG I. COLEMAN ◽

WILLIAM H. HERMAN ◽

JENNIFER CAI ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Real World ◽

Comparative Effectiveness ◽

Receptor Agonist ◽

Treatment Patterns ◽

Glucagon Like Peptide ◽

Effect of exercise combined with glucagon-like peptide-1 receptor agonist treatment on cardiac function: A randomized double-blind placebo-controlled clinical trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.12900 ◽

2017 ◽

Vol 19 (7) ◽

pp. 1040-1044 ◽

Cited By ~ 15

Author(s):

Peter G. Jørgensen ◽

Magnus T. Jensen ◽

Pernille Mensberg ◽

Heidi Storgaard ◽

Signe Nyby ◽

...

Keyword(s):

Clinical Trial ◽

Cardiac Function ◽

Receptor Agonist ◽

Controlled Clinical Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Glucagon Like Peptide ◽

Efficacy and safety of switching from a dipeptidyl peptidase-4 inhibitor to a glucagon-like peptide-1 receptor agonist: A real-world experience

Endocrine Abstracts ◽

10.1530/endoabs.70.aep487 ◽

2020 ◽

Author(s):

Carolina García-Figueras-Mateos ◽

Manuel Cayón-Blanco

Keyword(s):

Real World ◽

Receptor Agonist ◽

Dipeptidyl Peptidase ◽

Efficacy And Safety ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Glucagon Like Peptide ◽

PDG15 ECONOMIC ASSESSMENT OF SWITCHING FROM DIPEPTIDYL PEPTIDASE-4 INHIBITORS TO SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS OR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST USING REAL-WORLD DATA

Value in Health ◽

10.1016/j.jval.2020.04.305 ◽

2020 ◽

Vol 23 ◽

pp. S131

Author(s):

S.K. Peasah ◽

K. Munshi ◽

E. Swart ◽

L. Neilson ◽

Y. Huang ◽

...

Keyword(s):

Real World ◽

Receptor Agonist ◽

Economic Assessment ◽

Dipeptidyl Peptidase ◽

Real World Data ◽

Dipeptidyl Peptidase 4 ◽

Sodium Glucose Cotransporter ◽

Dipeptidyl Peptidase 4 Inhibitors ◽

Glucagon Like Peptide ◽